FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors

被引：0
|
作者：
Lacombe, C. [1 ]
Perrier, M. [2 ]
Hentic, O. [1 ]
Brixi, H. [2 ]
Rebours, V [1 ]
Cadiot, G. [2 ]
Ruszniewski, P. [1 ]
de Mestier, L. [1 ]
机构：
[1] Univ Paris, Beaujon Hosp, APHP Nord, Dept Gastroenterol Pancreatol, Clichy, France
[2] Univ Reims, Robert Debre Hosp, Dept Hepatogastroenterol & Digest Oncol, Reims, France
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
neuroendocrine tumor; antiangiogenic therapy; vegf; well-differentiated;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
I17
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [31] Treatment of metastatic disease in patients with neuroendocrine tumors
    Niederhuber, John E.
    Fojo, Tito
    SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 15 (03) : 511 - +
  • [32] LONG-TERM BEVACIZUMAB TREATMENT IN PATIENTS WITH METASTATIC COLORECTAL CANCER WHO ARE RECEIVING FOLFOX4 AND FOLFIRI CHEMOTHERAPY
    Davidenko, Irina
    Kazantseva, Margarita
    Potemin, Sergey
    Elizbaryan, Karina
    Mamaeva, Elena
    Burdik, Oksana
    ANNALS OF ONCOLOGY, 2012, 23 : 98 - 98
  • [33] Axitinib (AG-013736) in combination with FOLFOX and bevacizumab (Bev) in patients (pts) with metastatic solid tumors: A phase I study
    Abhyankar, V. V.
    Sharma, S.
    Trowbridge, R. C.
    Robles, R. L.
    Tarazi, J. C.
    Kim, S.
    Tortorici, M.
    Hee, B.
    Burgess, R. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in Patients with Neuroendocrine Tumors
    Eriksson, Barbro
    Annibale, Bruno
    Bajetta, Emilio
    Mitry, Emmanuel
    Pavel, Marianne
    Platania, Marco
    Salazar, Ramon
    Ploeckinger, Ursula
    NEUROENDOCRINOLOGY, 2009, 90 (02) : 214 - 219
  • [35] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [36] Chemotherapy of metastatic neuroendocrine gastroenteropancreatic tumors with streptozotocin and 5-fluorouracil.
    Faiss, S
    Riecken, EO
    Wiedenmann, B
    GASTROENTEROLOGY, 2000, 118 (04) : A517 - A517
  • [37] Chemotherapy in Neuroendocrine Tumors
    Das, Satya
    Al-Toubah, Taymeyah
    Strosberg, Jonathan
    CANCERS, 2021, 13 (19)
  • [38] Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis
    Shui, Lin
    Wu, Yu-Shen
    Lin, Huapeng
    Shui, Pixian
    Sun, Qin
    Chen, Xiaopin
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 48 (05) : 1870 - 1881
  • [39] Modified FOLFOX6 Chemotherapy in Patients with Metastatic Urachal Cancer
    Yanagihara, Yutaka
    Tanji, Nozomu
    Miura, Noriyoshi
    Shirato, Akitomi
    Nishimura, Kenichi
    Fukumoto, Tetsuya
    Azuma, Koji
    Miyauchi, Yuki
    Kikugawa, Tadahiko
    Yokoyama, Masayoshi
    CHEMOTHERAPY, 2013, 59 (06) : 402 - 406
  • [40] MicroRNAs as outcome predictors in patients with metastatic colorectal cancer treated with bevacizumab in combination with FOLFOX
    Kiss, I.
    Mlcochova, J.
    Souckova, K.
    Fabian, P.
    Poprach, A.
    Halamkova, J.
    Svoboda, M.
    Vyzula, R.
    Slaby, O.
    ONCOLOGY LETTERS, 2017, 14 (01) : 743 - 750
12345